Oral IL-23 Antagonist Icotrokinra Improves PsA Symptoms
Summary
The phase 3 trial finds improvements in joint response, physical function, and skin clearance, with no new safety signals at 16 weeks.
Description from Medscape.
Who is covering this
-
Oral IL-23 Antagonist Icotrokinra Improves PsA Symptoms
The phase 3 trial finds improvements in joint response, physical function, and skin clearance, with no new safety signals at 16 weeks.
Comments
Comments need JavaScript.